Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gflas Life Sciences Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, which indicates a focused prosecution effort for the company's active patent application. The data also shows 1 distinct art unit, suggesting that the current workload is concentrated within a single technical group at the patent office.
The busiest examiner for the portfolio is CHATTERJEE, JAYANTA, who is responsible for 1 busiest examiner pending action. This figure accounts for the total volume of 1 pending office action for the company. Because the prosecution involves only 1 distinct examiner and 1 distinct art unit, the process is highly centralized. Practitioners should focus on the specific tendencies and requirements of this examiner within the biotechnology field. The current state of the portfolio reflects a narrow but clear prosecution path for the company's intellectual property in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHATTERJEE, JAYANTA | 1 | 44.0% | +70.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18832478 | TOMATOES CONTAINING HIGH LEVELS OF 7-DEHYDROCHOLESTEROL AND PREPARATION METHOD THEREFOR | CHATTERJEE, JAYANTA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18832478 | TOMATOES CONTAINING HIGH LEVELS OF 7-DEHYDROCHOLESTEROL AND PREPARATION METHOD THEREFOR | CHATTERJEE, JAYANTA | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18832478 | TOMATOES CONTAINING HIGH LEVELS OF 7-DEHYDROCHOLESTEROL AND PREPARATION METHOD THEREFOR | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Non-Final OA | — | Pending | Jul 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGflas Life Sciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jayanta Chatterjee has the most, with 1 of Gflas Life Sciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
